MYGN

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Peers: FLGT GRAL VCYT NTRA BLLN DGX LH A DHR TMO

| Held by: XBI IWM VTI IWN VXF FESM IBB FNDA SCHA VTWO

Index	RUT
Market Cap	534.57M
Enterprise Value	621.67M
Income	-399.90M
Sales	829.00M
Book/sh	3.57
Cash/sh	1.32
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2700
IPO	Oct 06, 1995

P/E	-
Forward P/E	37.46
PEG	0.57
P/S	0.64
P/B	1.58
P/C	4.30
P/FCF	-
EV/EBITDA	-
EV/Sales	0.75
Quick Ratio	2.19
Current Ratio	2.40
Debt/Eq	0.63
LT Debt/Eq	0.61
Option/Short	Yes / Yes

EPS (ttm)	-4.32
EPS next Y	0.15
EPS next Q	-0.06
EPS this Y	2.08%
EPS next Y	146.71%
EPS next 5Y	65.44%
EPS past 3/5Y	-41.67% -8.03%
Sales past 3/5Y	6.72% 5.24%
EPS Y/Y TTM	-286.80%
Sales Y/Y TTM	-0.28%
EPS Q/Q	-32981.82%
Sales Q/Q	2.30%
Earnings	May 05 AMC
EPS/Sales Surpr.	-32.35% -1.00%

Insider Own	6.98%
Insider Trans	2.12%
Inst Own	93.64%
Inst Trans	-5.15%
ROA	-47.61%
ROE	-76.73%
ROIC	-73.81%
Gross Margin	66.14%
Oper. Margin	-7.73%
Profit Margin	-48.24%
SMA20	19.22%
SMA50	26.18%
SMA200	-2.53%
Trades

Shs Outstand	94.40M
Shs Float	87.86M
Short Float	9.85%
Short Ratio	5.38
Short Interest	8.65M
52W High	8.59 -34.11%
52W Low	3.53 60.34%
Volatility	8.40% 7.32%
ATR (14)	0.33
RSI (14)	68.81
Beta	1.60
Rel Volume	1.24
Avg Volume	1.61M
Volume	245,018

Perf Week	22.25%
Perf Month	42.57%
Perf Quarter	29.82%
Perf Half Y	-12.65%
Perf YTD	-7.97%
Perf Year	6.59%
Perf 3Y	-75.58%
Perf 5Y	-81.49%
Perf 10Y	-81.50%
Recom	2.89
Target Price	6.38
Prev Close	5.85
Price	5.66
Change	-3.25%

Date	Action	Analyst	Rating Change	Price Target Change
May-21-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$6
May-08-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$6
Apr-09-25	Downgrade	Guggenheim	Buy → Neutral
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight	$11.50 → $12.50
Feb-12-25	Initiated	Craig Hallum	Buy	$29
Dec-10-24	Initiated	UBS	Neutral	$18
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$30 → $21
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight	$32
Aug-28-24	Initiated	Wells Fargo	Overweight	$35
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$29
Jun-03-24	Resumed	Jefferies	Underperform	$20
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform	$25 → $35
Dec-21-23	Resumed	Piper Sandler	Neutral	$23
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$20
Dec-14-23	Initiated	Guggenheim	Buy	$23
Dec-13-23	Initiated	Wolfe Research	Outperform	$28
Jul-05-23	Resumed	JP Morgan	Underweight	$18
May-23-23	Upgrade	Goldman	Sell → Buy	$18 → $25
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$25

Show Previous Ratings

Jun-23-26 09:05AM	Myriad Genetics Expands Availability of Precise MRD for Colorectal, Renal and Breast Cancers, Supported by New Publication (GlobeNewswire)
Jun-02-26 09:05AM	Myriad Genetics Names Raj Jampa as New Chief Technology Officer (GlobeNewswire)
May-27-26 09:05AM	Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting (GlobeNewswire)
May-26-26 04:05PM	Myriad Genetics Launches Prolaris + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) (GlobeNewswire)
May-15-26 11:00AM	Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life (GlobeNewswire)
04:05PM	Loading…
May-07-26 04:05PM	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
May-06-26 08:30AM	Myriad Genetics, Inc. Q1 2026 Earnings Call Summary (Moby) -18.29%
May-05-26 05:14PM	Myriad: Q1 Earnings Snapshot (Associated Press)
04:05PM	Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business (GlobeNewswire)
Apr-30-26 09:05AM	Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan (GlobeNewswire)
Apr-28-26 04:05PM	Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 (GlobeNewswire)
Apr-16-26 09:15AM	Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 (GlobeNewswire)
Apr-14-26 09:15AM	Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan (GlobeNewswire) +6.97%
Apr-09-26 09:15AM	Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting (GlobeNewswire) -6.92%
Mar-17-26 04:05PM	Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer (GlobeNewswire)
12:40PM	Loading…
Mar-10-26 12:40PM	Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know (StockStory) +6.44%
Mar-06-26 06:39PM	Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 (PR Newswire) -6.60%
Mar-03-26 03:35PM	Myriad Genetics (MYGN) Stock Trades Up, Here Is Why (StockStory) +5.59%
Mar-02-26 04:05PM	Myriad Commercially Launches Precise MRD with Select Community Oncologists (GlobeNewswire) +8.68%
Feb-24-26 11:25AM	Why Myriad Genetics (MYGN) Stock Is Trading Up Today (StockStory)
09:00AM	Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk tests (GlobeNewswire)
08:30AM	Myriad Genetics, Inc. Q4 2025 Earnings Call Summary (Moby)
07:45AM	MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down (Zacks)
12:02AM	Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights: Surpassing Revenue Expectations ... (GuruFocus.com)
Feb-23-26 08:00PM	Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings (Zacks)
07:25PM	Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates (Zacks)
06:18PM	Myriad Genetics Q4 Earnings Call Highlights (MarketBeat)
04:52PM	Myriad: Q4 Earnings Snapshot (Associated Press Finance)
04:21PM	Myriad Genetics's (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22% (StockStory)
04:05PM	Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution (GlobeNewswire)
12:07PM	Loading…
12:07PM	Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting (MarketBeat)
Feb-19-26 09:15AM	FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test (GlobeNewswire)
Feb-18-26 09:15AM	Ahead of Myriad (MYGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-16-26 04:15PM	Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 (GlobeNewswire)
Feb-12-26 08:02PM	Zydus Lifesciences Ltd (BOM:532321) Q3 2026 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) -6.60%
Feb-10-26 10:07PM	Quest Diagnostics Q4 Earnings Call Highlights (MarketBeat)
Jan-27-26 08:50AM	Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data (GlobeNewswire)
Jan-21-26 11:36PM	2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm (StockStory)
Jan-13-26 07:30AM	TEM's Collab for Oncology Patient Population Is Gaining Attention (Zacks) -5.63%
Jan-12-26 08:30AM	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance (GlobeNewswire)
Jan-05-26 04:15PM	Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.19%
Dec-30-25 08:06AM	Should Myriad Genetics Stock Stay in Your Portfolio Right Now? (Zacks)
Dec-22-25 03:01PM	Myriad Genetics (MYGN) Stock Trades Up, Here Is Why (StockStory)
Dec-09-25 02:16PM	Why Myriad Genetics (MYGN) Stock Is Up Today (StockStory)
09:00AM	Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-08-25 11:03PM	Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Dec-04-25 11:30AM	Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? (Zacks)
Dec-03-25 11:30AM	Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? (Zacks)
Dec-02-25 11:34PM	1 Healthcare Stock with Promising Prospects and 2 We Question (StockStory)
Dec-01-25 12:36PM	Why Myriad Genetics (MYGN) Stock Is Trading Lower Today (StockStory) -7.47%
Nov-25-25 04:15PM	Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health (GlobeNewswire)
Nov-24-25 07:00PM	Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know (StockStory)
Nov-19-25 12:45PM	Why Myriad Genetics (MYGN) Stock Is Up Today (StockStory)
Nov-18-25 10:36PM	Q3 Earnings Roundup: Myriad Genetics (NASDAQ:MYGN) And The Rest Of The Therapeutics Segment (StockStory)
Nov-17-25 08:55AM	How Did Tempus AI Power Its Move to Positive EBITDA in Q3? (Zacks)
Nov-11-25 09:00AM	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Nov-10-25 08:30AM	Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk Hereditary Cancer Test to Support Evolving Clinical Needs (GlobeNewswire)
12:31AM	The Top 5 Analyst Questions From Myriad Genetics's Q3 Earnings Call (StockStory)
Nov-06-25 08:30AM	Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference (GlobeNewswire)
Nov-04-25 11:56AM	Why Myriad Genetics (MYGN) Stock Is Down Today (StockStory) -21.03%
08:46AM	MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds (StockStory)
12:00AM	Myriad Genetics Inc (MYGN) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with ... (GuruFocus.com)
Nov-03-25 07:00PM	Myriad (MYGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:40PM	Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3 (Zacks)
05:27PM	Myriad Genetics's (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops (StockStory)
04:40PM	Myriad: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution (GlobeNewswire)
Nov-01-25 11:07PM	What To Expect From Myriad Genetics's (MYGN) Q3 Earnings (StockStory)
Oct-31-25 09:28AM	Earnings To Watch: Myriad Genetics Inc (MYGN) Reports Q3 2025 Result (GuruFocus.com)
09:05AM	New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner (GlobeNewswire)
Oct-27-25 04:15PM	Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-17-25 12:36AM	2 Unpopular Stocks That Deserve a Second Chance and 1 That Underwhelm (StockStory)
Oct-14-25 08:00AM	Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel (GlobeNewswire)
Oct-10-25 03:51PM	Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know (StockStory)
Oct-08-25 08:20AM	Hologic Expands Panther Fusion's Menu With Diagnostic Innovation (Zacks)
Oct-02-25 09:15AM	Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker (Zacks)
Oct-01-25 11:31PM	A Look Back at Therapeutics Stocks' Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack (StockStory) +6.92%
Sep-23-25 08:01AM	Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy (PR Newswire)
Sep-17-25 12:34AM	3 Small-Cap Stocks That Concern Us (StockStory)
Sep-16-25 08:20AM	Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now? (Zacks)
Sep-08-25 08:14AM	MYGN Stock Might Gain on The Lancet Study Backing Precise MRD (Zacks)
Sep-05-25 10:56AM	MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain? (Zacks)
12:39AM	3 Russell 2000 Stocks with Open Questions (StockStory)
Sep-04-25 07:00PM	Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology (GlobeNewswire)
Sep-03-25 04:30PM	New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression (GlobeNewswire)
Aug-27-25 04:05PM	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Aug-20-25 02:00AM	ANGLE Announces Collaboration with Myriad Genetics (ACCESSWIRE)
Aug-18-25 08:30AM	Myriad Genetics Appoints Ben Wheeler Chief Financial Officer (GlobeNewswire)
12:36AM	3 Healthcare Stocks We're Skeptical Of (StockStory)
Aug-13-25 08:00AM	New Myriad Genetics Survey Uncovers Women Fear Screenings-But Feel Reassured by the Results (GlobeNewswire)
12:11AM	Myriad Genetics's Q2 Earnings Call: Our Top 5 Analyst Questions (StockStory)
12:10AM	MYGN Q2 Deep Dive: Oncology Strategy Shift and Product Execution Shape Guidance (StockStory)
Aug-12-25 10:00AM	RxPreferred Benefits Expands Executive Leadership Team with Strategic Appointment and Key Promotions (PR Newswire)
12:03AM	3 Reasons MYGN is Risky and 1 Stock to Buy Instead (StockStory)
Aug-11-25 07:45AM	TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN) (Insider Monkey)
Aug-06-25 04:57PM	CareDx Announces Appointment of Nathan Smith as Chief Financial Officer (Business Wire) +46.51% +7.58%
01:11PM	Why Is Myriad Genetics (MYGN) Stock Soaring Today (StockStory)
Aug-05-25 06:30PM	Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics (Zacks)
05:55PM	Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:52PM	Myriad: Q2 Earnings Snapshot (Associated Press Finance)

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

PresidentMr. Samraat S. Raha

CFO & Principal Accounting OfficerMr. Benjamin R. Wheeler

Chief Operating OfficerMr. Mark S. Verratti

Chief Scientific OfficerDr. Dale Muzzey Ph.D.

ConsultantMr. Paul J. Diaz J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kumar Rashmi	Director	Jun 08 '26	Sale	4.46	15,000	66,843	171,889	Jun 09 04:20 PM
Kumar Rashmi	Director	Jun 08 '26	Proposed Sale	4.59	15,000	68,850		Jun 08 11:17 AM
Bisaro Paul	Director	May 14 '26	Buy	3.69	7,500	27,638	97,441	May 14 05:16 PM
Raha Samraat S.	President and CEO	Mar 09 '26	Buy	5.00	40,000	199,844	493,104	Mar 09 07:03 PM
Phanstiel S. Louise	Director	Feb 26 '26	Buy	4.80	50,407	242,105	233,951	Feb 27 04:46 PM
Phanstiel S. Louise	Director	Feb 27 '26	Buy	4.66	48,000	223,728	281,951	Feb 27 04:46 PM
Phanstiel S. Louise	Director	Feb 25 '26	Buy	4.74	6,100	28,890	183,544	Feb 27 04:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Myriad Genetics Inc

Upgrade your Finviz experience